Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Transplantation. 2020 May;104(5):1058–1069. doi: 10.1097/TP.0000000000002917

Figure 3: Effector memory CD8+ T cells emerging under belatacept have increased p-RPS6 expression.

Figure 3:

PBMCs isolated from patients 6 (A) and 7 (B, C) (n=2) undergoing rejection were analyzed for p-RPS6 before and after (1 and 2 weeks) mTORi. PBMCs were cultured alone, or with their respective donor APCs (allo) for 2 hours. Cells were then fixed and stained for CD45, CD3, CD8, CD38, CD28 and p-RPS6 phospho-flow analysis. Blue dashed-line histograms show isotype control. B) Allo reactive cells were detected by cell trace violet dilution in a mixed lymphocyte reaction assay in PBMCs of patient 7 at PTD 56 following rejection standard of care treatment were mixed with donor cells for 5 days and analyzed by flow cytometry.